📰 Mathilde Bohin News
Page 3 - Mathilde Bohin News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mathilde Bohin. Real-time updates on events, politics, business and more.
June 10, 2022
Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans) (Paris:ALIMP), a medical technology company specializing in vertebral implants, informs
June 2, 2022
76.88% of the Company's share capital was represented at the AGM and resolutions were all widely approved Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company
May 18, 2022
Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral implants, informs its shareholders
May 10, 2022
Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO) (Paris:GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis
April 19, 2022
Q1 2022 revenue doubles to €2.02 million (vs. Q1 2021), driven by the organic growth of its JAZZ activity and the strategic acquisition of OSD Acceleration in activity in France (x2.7) and
April 7, 2022
Group turnover up by 23% at €31.3 millionOperating income and revenue of €36.2M, offsetting the foreseen discontinuation of the GSK subsidy (€8M)R&D investments amounting to €7.4MNet profit/loss near the break-even point (-€0.3M)Service BU:Very strong organic growth in external turnover at +31%, reaching €27.6M,EBIT...
April 7, 2022
Group turnover up by 23% at €31.3 million Operating income and revenue of €36.2M, offsetting the foreseen discontinuation of the GSK subsidy (€8M) R&D investments amounting to €7.4M
March 15, 2022
Successful strategic repositioning: strengthening of the Spine business (+62% in 2021) with the acquisition of OSD and divestment of MADISONTM Sharp increase of 46% in the gross margin, to
February 22, 2022
First synergies with OSD products in the United States Strengthening of Implanet's presence in the U.S. Spine market Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168,
February 8, 2022
Collaboration combines SEngine's PARIS Test platform for drug screening on live patient-derived tumor cells and Oncodesign's Nanocyclix technology for generation of novel kinase inhibitors Regulatory